Saudi Arabia Pain Management Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Acetaminophen, Opioid (Strong Opioid, Weak Opioid), Antidepressants, Anticonvulsant Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Cancer, Rheumatoid Arthritis, Chronic Back Pain, Post-Operative Pain, Others), And By Cities - Forecasts From 2025 To 2030

Saudi Arabia Pain Management Drugs Market Size:

Saudi Arabia pain management drugs market is anticipated to grow at a CAGR of 4.55% from 2025 to 2030.

The Saudi Arabian government has been focusing most of its efforts on developing the medical tourism sector in the country, which is evident from the fact that the healthcare sector in Saudi Arabia is being focused on a lot under the Country’s Vision 2030 program. As part of this program, the government is diverting the funds towards the development of new hospitals and robust healthcare infrastructure which are instrumental in attracting tourists seeking state-of-the-art and cost-effective healthcare services.

In conjunction, the government is implementing policies aimed at making the process of attaining a Visa for medical treatment in the kingdom easy for people worldwide. As this continues, and number of people undergoing medical treatments in this country continues to increase, the demand for pain management drugs can be expected to show a solid increase over the projected period.

Hence, the increased population has also escalated the frequency of old-age people prone to various health issues. Hence, the growing chronic conditions among old-age people are set to pave the way for future market demand for pain management drugs. As per the General Authority for Statistics, by mid-2024, the Kingdom’s total population reached 35.3 million with an average growth rate of 4.7%. Moreover, as per the United Nations Population Fund, from 2020 to 2050 the population aged 60 and above will show a five-fold increase. Hence, such growing numbers are expected to drive the essence of self-medication awareness among people in Saudi Arabia, thereby adding to the overall market growth.

Moreover, the growing demand for opioid-free pain relief drugs followed by regulations on new drug development in Saudi Arabia has provided new prospects for market players to follow the given standards for improving their presence. In February 2024, Hikma Pharmaceuticals Plc announced its signing of the licensing agreement with AFT Pharmaceuticals for the registration & commercialization of the former’s “Combogesic® IV” which is an opioid-free pain relief drug suitable for treating short-term acute pain in adults. The medicine also finds its way to reducing fever.

Saudi Arabia Pain Management Drug Market Segmentation

• By Drug Type
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Acetaminophen
  • Opioid
    • Strong Opioid
    • Weak Opioid
  • Antidepressants
  • Anticonvulsant Drugs
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Indication
  • Cancer
  • Rheumatoid Arthritis
  • Chronic Back Pain
  • Post-Operative Pain
  • Others
• By Cities
  • Riyadh
  • Mecca
  • Jeddah
  • Medina
  • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies 

6.4. Online Pharmacies

7. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET BY CITY

8.1. Introduction

8.2. Riyadh

8.2.1. By Drug Type

8.2.2. By Distribution Channel

8.2.3. By Indication

8.3. Mecca

8.3.1. By Drug Type

8.3.2. By Distribution Channel

8.3.3. By Indication

8.4. Jeddah

8.4.1. By Drug Type

8.4.2. By Distribution Channel

8.4.3. By Indication

8.5. Medina

8.5.1. By Drug Type

8.5.2. By Distribution Channel

8.5.3. By Indication

8.6. Others

8.6.1. By Drug Type

8.6.2. By Distribution Channel

8.6.3. By Indication

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Novartis Pharmaceuticals Corporation (Novartis AG)

10.2. Eli Lilly and Company

10.3. Pfizer Inc.

10.4. GlaxoSmithKline plc

10.5. Sanofi S.A

10.6. Johnson & Johnson

10.7. Viatris Inc.

10.8. The Menarini Group

10.9. Hikma Pharmaceuticals Plc

10.10. Abbott Laboratories

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

 Novartis Pharmaceuticals Corporation (Novartis AG)

Eli Lilly and Company

Pfizer Inc.

GlaxoSmithKline plc

Sanofi S.A

Johnson & Johnson

Viatris Inc.

The Menarini Group

Hikma Pharmaceuticals Plc

Abbott Laboratories